SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Amgen

130

Amgen

AMGN

The Thousand Oaks, Calif.-based biotech pharmaceutical company makes drugs that treat patients in about 100 countries.

Looking for leads, investment insights, or competitive intelligence?

CEO

Robert A. Bradway

CEO Title

Chairman, President & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Thousand Oaks, Calif.

Years on Fortune 500 List

19

Employees

20,800

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$22,849-0.6%
Profits ($M)$1,979.0-74.4%
Assets ($M)$79,954
Total Stockholder Equity ($M)$25,241
Market Value — as of March 29, 2018 ($M)$122,842
Profit Ratios
Profit as % of Revenues8.7%
Profits as % of Assets2.5%
Profits as % of Stockholder Equity7.8%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)2.69
EPS % Change (from 2016)-73.7%
EPS % Change (5 year annual rate)-13.4%
EPS % Change (10 year annual rate)-0.5%
Total Return
Total Return to Investors (2017)22.1%
Total Return to Investors (5 year, annualized)17.6%
Total Return to Investors (10 year, annualized)15.7%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Amgen

Why Amgen Is Lowering the Price of Cholesterol Drug Repatha By 60%

Amgen says Repatha sold $271 million in the first half of 2018, despite earlier predictions of multi-billion-dollar sales.

Read More →
Tech's Next Big Wave: Big Data Meets Biology

Just about everyone agrees that America's health care system is broken. Is better data—and the ability to harness it—the medicine we've been looking for?

Read More →
Amgen Is Taking On a $3 Billion Cancer Drug. But Will It Cut Costs for Patients?

The FDA approved the first cancer medicine "biosimilar" Thursday.

Read More →